pharma · Kidney Dysfunction · Obesity
LianBio
Jian Li
LianBio clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2019
- Employees
- 47
- Programs
- 28
- Drugs
- 40
- Patents
- 0
LianBio projects
4 ClinicalTrials.gov programs sponsored by LianBio.
LianBio has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
HS-20094 Injection
Jian Li
Type 2 Diabetes
1 trial -
Irinotecan liposome、5-Fluorouracil、Leucovorin
Jian Li
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
1 trial -
Placebos
Jian Li
Advanced Non-small Cell Lung Cancer
1 trial -
SHR-1210
Jian Li
Locally Advanced or Metastatic and Unresectable HCC
1 trial
Frequently asked questions
How many clinical projects does LianBio have?
4 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.